What is Zevra Therapeutics, Inc.'s business segments — R&D?

Zevra Therapeutics, Inc. (ZVRA) reported business segments — R&D of $2.93M in Q1 2026.

How has Zevra Therapeutics, Inc.'s business segments — R&D changed year-over-year?

Zevra Therapeutics, Inc.'s business segments — R&D increased by 24.2% year-over-year, from $2.36M to $2.93M.

What does business segments — R&D mean?

Captures the direct costs associated with research and development activities specifically identified to the segment's drug pipeline. Monitoring these expenditures is essential for evaluating the company's commitment to innovation and the progression of its rare disease therapeutic portfolio.

Zevra Therapeutics, Inc. ZVRA Business Segments — R&D

Similar metrics at other companies

INDVReportable Segment — R&D

$16M-27.3%

TARSReportable Segment — R&D

$22.35M+55.1%

TVTXReportable Segment — R&D

$57.09M+21.8%

ARDXReportable Segment — R&D

$17.59M+55.1%

ZYMEReportable Segment — R&D

$34.46M-3.6%

NVAXReportable Segment — R&D

$38.06M-4.6%

Other financials

Income statement

See full

Revenue$36.2M+77.5%

Gross profit$34.3M+80.1%

Operating income$52.1M+1,073%

Net income$37.9M+1,323%

EPS (diluted)$0.60+1,100%

Balance sheet

See full

Cash & equivalents$95.6M+156%

Total debt$1.1M-98.1%

Total equity$205.8M+402%

Total assets$278.6M+61.3%

Cash flow

See full

Operating cash flow$6.1M+175%

CapEx$35.0K-64.6%

Free cash flow$6.1M+173%

Valuation

See full

Market cap$782.09M+58.2%

Enterprise value$687.64M+32.5%

P/E6.3×—

P/S6.4×-5.8×

Profitability

See full

Gross margin86.1%+7.2pp

Operating margin-103.9%-43.0pp

Net margin101.6%+60.1pp

FCF margin-75%-30.5pp

Returns & leverage

See full

Return on equity100.7%+60.3pp

Debt / equity0×-1.5×

Current ratio4.9×+1.9×

Where this comes from

Reported directly by Zevra Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zevra Therapeutics, Inc.'s business segments — r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Zevra Therapeutics, Inc.'s business segments — R&D?: Zevra Therapeutics, Inc. (ZVRA) reported business segments — R&D of $2.93M in Q1 2026.
How has Zevra Therapeutics, Inc.'s business segments — R&D changed year-over-year?: Zevra Therapeutics, Inc.'s business segments — R&D increased by 24.2% year-over-year, from $2.36M to $2.93M.
What does business segments — R&D mean?: Captures the direct costs associated with research and development activities specifically identified to the segment's drug pipeline. Monitoring these expenditures is essential for evaluating the company's commitment to innovation and the progression of its rare disease therapeutic portfolio.